Key result
Pravastatin significantly reduced vascular superoxide production and normalized serum Glycer-AGE levels in a rat model of type 2 diabetes, independent of cholesterol-lowering activity.
Why the study?
Does pravastatin reduce vascular superoxide production and serum Glycer-AGEs in a rat model of type 2 diabetes?
Does pravastatin reduce vascular superoxide production and serum Glycer-AGEs in a rat model of type 2 diabetes?
Pravastatin reduces vascular superoxide production in a rat model of type 2 diabetes by inhibiting Glycer-AGE production, independent of its cholesterol-lowering effects.
Answers are grounded in this paper and cite their sources.
Supports pleiotropic effects in diabetic rat models; hypothesis-generating and leaves open human translation.
A complication of diabetes mellitus is the over-production of vascular superoxides, which contribute to the development of arteriosclerosis and peripheral arterial disease (PAD). Hyperglycemia induces the formation and accumulation of advanced glycation end-products (AGEs), which in turn stimulate vascular superoxide production. The mechanism underlying AGE-mediated vascular superoxide production remains to be clarified in lower limb complications associated with diabetes. In the present study, we investigated the role of AGEs and the mitochondrial respiratory complex in superoxide production in femoral arteries using the type 2 diabetes model Otsuka Long-Evans Tokushima Fatty (OLETF) rats [vs. non-diabetic Long-Evans Tokushima Otsuka (LETO) rats]. The effects of in vivo administration of pravastatin on superoxide production in femoral arteries were also examined. Using chemiluminescent assays, luminescence microscopy, and competitive enzyme-linked immunosorbent assay (ELISA), we determined that vascular superoxide production and serum glyceraldehyde-derived AGEs (Glycer-AGEs) increased in OLETF rats. Pravastatin inhibited these responses without changing serum total cholesterol concentrations. The mitochondrial complex II inhibitor thenoyltrifluoroacetone (TTFA) also inhibited vascular superoxide production. Application of Glycer-AGEs in situ increased superoxide production in the vascular wall of femoral arteries from pravastatin-treated OLETF rats, which was then inhibited by TTFA. These results suggest that hyperglycemia increases serum Glycer-AGEs, which subsequently induce superoxide production in the femoral artery of OLETF rats in a mitochondrial complex II-dependent manner. Collectively, our results have partially elucidated the pathological mechanisms leading to diabetes-related PAD, and indicate dual beneficial actions of pravastatin for the prevention of oxidative damage to the vascular wall.
No takes yet. Share an insight, caveat, or question.
Hori et al. (2017) studied Type 2 diabetes (animal model) (n=60). Pravastatin vs. Untreated OLETF rats was evaluated on Vascular superoxide production and serum Glycer-AGEs (p=<0.01). Pravastatin significantly reduced vascular superoxide production and normalized serum Glycer-AGE levels in a rat model of type 2 diabetes, independent of cholesterol-lowering activity.
Synapse has enriched 10 related papers. Consider them for comparative context: